Table 1.
Clinico-pathological features of 61 patients with triple negative breast cancer
| Variables | N (%) | |
|---|---|---|
| Median (IQR) age, years | 57 (31–84) | |
| Age, n (%) | ≤ 50 years | 22 (36.1) |
| > 50 years | 39 (63.9) | |
| Menstrual status at referred, n (%) | Yes, physiological | 13 (46.4) |
| Yes, post-surgical | 4 (46.4) | |
| No | 11 (39.3) | |
| Site, n (%) | Right | 31 (53.5) |
| Left | 26 (44.8) | |
| Bilateral | 1 (1.7) | |
| Histologic subtype, n (%) | Invasive ductal carcinoma (NST) | 40 (65.6) |
| Medullary carcinoma | 9 (14.8) | |
| Metaplastic carcinoma | 4 (6.6) | |
| Other | 8 (13.1) | |
| Tumor size, n (%) | ≤ 20 mm | 34 (55.7) |
| > 20 mm | 27 (44.3) | |
| Pathologic tumor classification, n (%) | pT1 | 24 (42.9) |
| pT2 | 26 (46.4) | |
| pT3 | 3 (5.4) | |
| pT4 | 3 (5.4) | |
| Regional lymph nodes involvement, n (%) | pN0 | 31 (53.5) |
| pN1 | 16 (27.6) | |
| pN2 | 6 (10.3) | |
| pN3 | 5 (8.6) | |
| Histologic grade, n (%) | G1 | 3 (4.9) |
| G2 | 8 (13.1) | |
| G3 | 50 (82.0) | |
| Tumor stage, n (%) | 1 | 13 (24.1) |
| 2 | 29 (53.7) | |
| 3 | 12 (22.2) | |
| Necrosis, n (%) | Present | 20 (35.1) |
| Absent | ||
| Tumor infiltrating lymphocytes, n (%) | Present | 27 (52.9) |
| Absent | 24 (40.1) | |
| Lymph vascular invasion, n (%) | Present | 13 (25.5) |
| Absent | 38 (74.5) | |
| Ki67, n (%) | ≤ 20% | 12 (19.7) |
| > 20% | 49 (80.3) | |
| AR, n (%) | < 10% | 38 (69.1) |
| ≥ 10% | 17 (30.9) | |
| Death, n (%) | 8 (13.1) | |
| Gene expression BCL11A | Down | 47 (77.1) |
| Up | 14 (23.0) | |
| Gene expression BCL11A_XL | Down | 37 (62.7) |
| Up | 22 (37.3) | |
| Gene expression BCL11A_L | Down | 35 (68.6) |
| Up | 16 (31.4) | |
| Gene expression BCL11A_S | Down | 42 (87.5) |
| Up | 6 (12.5) | |
| Protein expression BCL11A | Low: 0–1 | 45 (73.8) |
| High: 2–8 | 16 (26.2) | |
IQR interquartile range, N number